血清CA19-9测定对胰腺癌和胆管癌的诊断价值

The Value of Serum CA199 for the Diagnosis of Pancreatic and Extrahepatic Bile Ductal Cancer

采用ＲＩＡ法测定１５８例胰腺和胆道良、恶性疾病和２０例正常人血清ＣＡ１９－９含量，部分病例同时测定血清ＰＯＡ、ＣＥＡ含量。结果：正常人血清ＣＡ１９－９含量较低（１３．４±１０．１Ｕ／ｍｌ），无一例阳性（＞３７Ｕ／ｍｌ）。胰腺癌和胆管癌ＣＡ１９－９阳性率分别为８４．４％、７３．８％，显著高于良性胰腺疾病组（２０．０％）和良性胆道疾病组（３０．４％）（Ｐ＜０．００５或Ｐ＜０．０１）。上段胆管癌ＣＡ１９－９阳性率也显著高于中、下段胆管癌（Ｐ＜０．０５）。血清ＣＡ１９－９测定对胰腺癌和胆管癌诊断敏感性７９．３％，特异性７９．１％，正确率８４．８％。ＣＡ１９－９、ＰＯＡ、ＣＥＡ联合检测可提高诊断胰腺癌的可用度。

he serum concentration of CA199 was measured in 158 patients with benign of malignant pancreatic and extrahepatic bile ductal diseases and in 20 healthy people as controls. In some cases, POA and CEA concentrations were also detected. In normal persons, serum concentration of CA199 was much lower, and none was positive. The positive rate of CA199 was 84.4%, and 73.8%, for pancreatic cancer and extrahepatic bile ductal carcinoma respectively. Their positive rates were significantly higher than that of benign pancreatic diseases (20%) and benign extrahepatic bile ductal cases (30.4%) (P<0.005 or 0.01). The sensitivity, specifity and validity of CA199 for the diagnosis of pancreatic and extrahepatic bile ductal cancer was 79.3%, 79.1% and 84.4%, repectively. Combined detection of CA199, POA, and CEA can increase the availability in the diagnosis of pancreatic cancer.